Welcome to our blog! This is where we share a bit more – insights, updates, and thoughts from Genovis. Take a look around and see what you find.
Search post
Category
The development of advanced gene therapies is promising and gives thousands of patients new hope for a curative treatment. However, many of the current gene therapies are using adeno-associated viruses as transporters of new genetic material. Up to 60% of patients may have antibodies against this viral vehicle and this is usually an exclusion criteria…
We're happy and proud to announce the launch of TransGLYCIT Azide Activation!
In a recent paper from Johns Hopkins University School of Medicine in Baltimore, removal of sialic acids from toll-like receptor 2 using SialEXO 23 was found to inhibit osteoclast fusion. These new findings in osteoclast recognition signaling are important for understanding the pathogenesis of different skeletal disorders, also showcasing the versatility of Genovis SmartEnzymes!
An inline electrochemical reduction workflow for antibodies coupled with LC-MS analysis is described in this paper from the National Institute for Bioprocessing Research and Training in Dublin. The FabRICATOR enzyme (IdeS) is a key component in the subunit analysis by digesting antibodies at a single site below the hinge, generating a homogenous pool of F(ab’)2…
In this study, scientists at Leiden University Medical Center present a MALDI FT-ICR MS method for the glycosylation profiling of intact erythropoietin (EPO). The sialidase mix SialEXO significantly reduced the mass spectrum complexity and facilitated the interpretation of the complex spectra of intact EPO.
The field of antibody-drug conjugates (ADCs) is rapidly emerging as a new, important class of cancer therapeutics. ADCs consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs, and after selective surface receptor binding on cancer cells, the drug is delivered into the intracellular compartment and can exert its cytotoxic effect.
We are happy to announce that PNGase F for in-solution hydrolysis of N-glycans from glycoproteins is added to our portfolio of SmartEnzymes!
We introduce FabDELLO, a protease that specifically digests human IgG1 at a single site above the hinge, generating intact Fab and Fc fragments within two hours with no need for reducing conditions. The enzyme is active on antibodies with mutated hinge regions and enables middle-level LC-MS for characterization of critical quality attributes.
Genovis launches Immobilized PNGase F, a resin with the PNGase F enzyme covalently coupled to agarose beads for hydrolysis of N-glycans on antibodies, fusion proteins and other N-glycosylated proteins in a convenient spin column format.
Our immune system protects us from pathogens and various diseases, and the immune response is dependent on a person’s repertoire of immune cells, antibodies and circulating plasma proteins. A detailed characterization of these plasma components is important for the understanding of how they affect each individual’s immune response.
In this paper, scientists at Spectroswiss and Orion Pharma present a novel strategy for DAR analysis of structurally complex antibody-oligonucleotide conjugates using SmartEnzymes™ and a proteoform integration approach combined with native SEC-Orbitrap FTMS.
Scientists at University of Geneva and Centre d’Immunologie Pierre-Fabre here describes a comprehensive intact and middle-level characterization of a commercial bispecific antibody by using a variety of orthogonal chromatographic methods coupled to MS.
